OS3 The TearLab Ocular Surface Severity Scale Benjamin D. Sullivan, Ph.D. (760)

Similar documents
Tear Osmolarity and its role in Optometric Practice & Contact Lens Success

VARIABILITY IS A HALLMARK OF DRY EYE DISEASE

A DRY EYE DISEASE DECISION TREE

Financial Disclosures

The first comprehensive definition of DED was published in

Investor Presentation. October 2018

pat hways Medtech innovation briefing Published: 15 December 2015 nice.org.uk/guidance/mib47

Optimizing the Ocular Surface. Presentation Title. Charlene M. Grice, Carolina Eyecare Physicians, LLC

Ocular Surface Disease. Advanced Treatment in Ocular Surface Disease. Disclosures. Revenue Potential. Chronic Dry Eye Should I Treat It

Dry eye syndrome (DES) is a prevalent condition, with

Evaluation of Dry Eye: A Hospital Based Study

Dry Eye Assessment and Management Study ELIGIBILITY OCULAR EVALUATION FORM

1. Department of Ophthalmology, Pacific Medical College and Hospital, Udaipur, Rajasthan, India

Ophthalmology Times Case Study Yasmin Mali, MD. Case Study

A Randomized Double-Masked Study of 0.05% Cyclosporine Ophthalmic Emulsion in the Treatment of Meibomian Gland Dysfunction

Ocular Surface Disease Workshop Walter O. Whitley, OD, MBA, FAAO Michael Cooper, OD Whitney Hauser, OD Scott Hauswirth, OD, FAAO

DRY EYE DISEASE is one of

Dry eye disease was recently redefined as a multifactorial

BREAKING THE VICIOUS CIRCLE OF DRY EYE DISEASE

Meibomian gland dysfunction

Does in-office manual expression for Meibomian Gland Dysfunction (MGD) work?

Prevalence of Dry Eye Disease

Conjunctivochalasis (Cch) is described as lax and redundant. The Impact of Conjunctivochalasis on Dry Eye Symptoms and Signs

Eyelid Thermal Pulsation for the Treatment of Dry Eye Syndrome

Although the prevalence

Incidence Of Dry Eye Disesase In People Living With Acquired Immuodeficiency Synrome

Forward Looking Statements

1/16/2018. William D. Townsend, O.D., F.A.A.O. Advanced Eye Care Canyon, TX Adjunct Professor UHCO Houston, TX.

The Tear Film! Cataract Surgery in the Diseased Eye: Ocular Surface Disease

QUALITATIVE INTERPRETATION OF VISUAL ACUITY IN DRY EYE PATIENTS

Dry Eye Disease Diagnosis and Treatment Pearls from the Trenches (2 hours) Mile Brujic, O.D Kensington Blvd. Bowling Green, OH 43402

CRITERIA FOR USE. A GRAPHICAL EXPLANATION OF BI-VARIATE (2 VARIABLE) REGRESSION ANALYSISSys

Eyelid Thermal Pulsation for the Treatment of Dry Eye Syndrome

Meibomian gland dysfunction (MGD) may well be the leading

Title: Keeping Step with DEWS2: Clinical Applications Lecturer: Scott G. Hauswirth, OD

HELP HEAL YOUR PATIENTS DRY EYES.

Dry eye, a common condition often manifested with visual

OVERCOMING THE CHALLENGES OF OPHTHALMIC DELIVERY USING AQUEOUS-FREE TECHNOLOGY: REDEFINING DRY EYE DISEASE

Advanced Diagnosis and Management of OSD and Tear Dysfunction

Immunology and Pathophysiology of Dry Eye

JMSCR Vol 05 Issue 02 Page February 2017

European Journal of Medical Sciences Eur J Med Sci Dec; 1(4): Tear Film Osmolarity in Diagnosis of Dry Eye Syndrome

Diagnostics. Traditionally, clinicians have made the diagnosis. cover story. Join the renaissance!

Considering Inflammation in Dry Eye Disease. Scott E. Schachter, O.D. Vision Source-Pismo Beach, CA

Disclosures and Special Request. Agenda. What s Up with OSD? Case 23/05/2013. OSD presents a significant challenge to

Ocular allergy. Anton van Biljon

Introducing a New Parameter for the Assessment of the Tear Film Lipid Layer

Diagnosing the severity of dry eye: a clear and practical algorithm

Author's response to reviews

Overview. NEI Definition of Dry Eye. Prevalence of Dry Eye 2/1/2018. The Dry Eye Story A Real Tear Jerker. Disclosures

1/23/2018. William D. Townsend, O.D., F.A.A.O. Advanced Eye Care Canyon, TX Adjunct Professor UHCO Houston, TX.

Visionary Optics. SynergEyes. North Suburban Vision Consultants, Ltd. Keratoconus Specialists of Illinois. S. Barry Eiden, OD, FAAO

Local Coverage Determination (LCD): Diagnostic Evaluation and Medical Management of Moderate-Severe Dry Eye Disease (DED) (L36232)

Technology appraisal guidance Published: 16 December 2015 nice.org.uk/guidance/ta369

Correlation between Tear Osmolarity and Other Ocular Surface Parameters in Primary Sjögren s Syndrome

Correlation of Tear Inflammatory Cytokines and Matrix Metalloproteinases with Four Dry Eye Diagnostic Tests METHODS. Reagents.

Matrix Metalloproteinase 9 Point-of-Care Immunoassay Result Predicts Response to Topical Cyclosporine Treatment in Dry Eye Disease

Prevalence of dry eye disease in type 2 diabetic patients and its co-relation with the duration, glycemic control and retinopathy

Dry eye disease is multifactorial in aetiology and complex in pathophysiology that makes its diagnosis clinically challenging.

Prevalence of Dry Eye in Patients Presenting With Symptoms Suggestive of Dry Eye

How to Create a Dry Eye Center

Automated Tear Film Surface Quality Breakup Time as a Novel Clinical Marker for Tear Hyperosmolarity in Dry Eye Disease

Hidenaga Kobashi, Kazutaka Kamiya*, Kyohei Yanome, Akihito Igarashi, Kimiya Shimizu. Abstract. Introduction

Tear Film Aberration Dynamics and Vision- Related Quality of Life in Patients with Dry Eye Disease

Dry eye disease (DED) is a common, yet complex,

Impact of Dry Eye Syndrome on Vision-Related Quality of Life in a Non-Clinic-Based General Population

Supplementary Online Content

Ocular Surface Dry Eye Disease

Spontaneous Eye Blink Patterns in Dry Eye: Clinical Correlations

Meibomian gland Dropout in Chinese cataract patients.

BARRY A. SCHECHTER ABSTRACT

Learning Objectives. Disclosures 2/2/ BMT Pharmacists Conference Bandage Contact Lens Therapy for Severe Ocular GVHD

Predisposing factors. Gender. Ocular Surface Disease. Ocular Surface Disease Health. Building a Dry Eye Practice

An Update on Diagnosis and Treatment of Refractory Ocular Surface Disease

DRY EYE TAKING AIM. How Systematic Management of this Chronic Disease is Improving Patient Outcomes. Sponsored by. A Supplement to

Incidence of dry eye in a sample population in Kuala Lumpur

Poly-unsaturated phospholipids WE (FA18:1) A B C D OAHFA 18:1/24:0 OAHFA 18:1/30:2 PS 38:4 C18:1C23:0 OAHFA 18:1/25:0 OAHFA 18:1/30:1

Research Article ABSTRACT INTRODUCTION. Saubhagya Sindhu 1, Shaktibala Dutta 1, Mirza Atif Beg 1, Sanjeev Kumar Mittal 2, Sushobhan Das Gupta 2

OCULAR SURFACE DISEASE SYNDROMES WAYNE ISAEFF, MD LOMA LINDA UNIVERSITY DEPARTMENT OF OPHTHALMOLOGY

Efficacy of Topical Pilocarpine in the Management of Primary Aqueous Tear Deficiency: An Initial Study

Effects of topical timolol and latanoprost by tear film evaluation and impression cytology.

Symptom Burden of Patients with Dry Eye Disease: A Four Domain Analysis

Overview & pathophysiology of Dry Eye and the use of cyclosporine eye drops in dry eye...

Effectiveness and relevant factors of 2 % rebamipide ophthalmic suspension treatment in dry eye

Dry eye syndrome (DES), as defined by

Inflammatory Cytokine and Osmolarity Changes in the Tears of Dry Eye Patients Treated with Topical 1% Methylprednisolone

The Ocular Surface. Rachel Redfern, OD, PhD, FAAO October 9, 2017

Current Treatment and Management of Dry Eye

Determination of the Minimal Clinically Important Difference of the UNC Dry Eye Management Scale. Christopher Hwang

Dry Eye Prescribing Guidelines

CONTACT LENSES AND DRY EYE

Managing Dry Eye Disease

Ocular Chronic Graft Versus-Host Disease after Hematopoietic Stem Cell Transplantation

Correlation of Bacterial Burden, Meibomian Gland Dysfunction and Ocular Surface Disease

A 5 Step Program. A 5 Step Program. A 5 step program. A 5 step Program 2/7/2018. A 5 Step Program Lens Settling Evidence.

Screening of dry eye disease in visual display terminal workers during occupational health examinations: The Moriguchi study

Evaporative dry eye disease (DED) is a pathological. Semifluorinated Alkane Eye Drops for Treatment of Dry Eye Disease Due to Meibomian Gland Disease

CLINICAL SCIENCES. Dry Eye Signs and Symptoms in Women With Premature Ovarian Failure

Optical Coherence Tomography Reveals Changes to Corneal Reflectivity and Thickness in Individuals with Tear Hyperosmolarity

Transcription:

OS3 The TearLab Ocular Surface Severity Scale Benjamin D. Sullivan, Ph.D. bdsulliv@tearlab.com (760) 224-4595 The Ocular Surface Severity Scale (OS 3 ) was originally developed as a way to compare the diagnostic performance of different objective signs of dry eye disease. The results of this analysis were recently published in IOVS, entitled An objective approach to dry eye disease severity: http://www.ncbi.nlm.nih.gov/pubmed/20631232 Formally, the OS 3 brings together common objective clinical tests for dry eye disease into a single unbiased composite score. These tests comprise tear osmolarity, Schirmer s test without anesthetic, fluorescein tear film breakup time (TBUT), corneal staining (NEI/Industry scale), the Ocular Surface Disease Index (OSDI), a meibomian dysfunction assessment (Bron/Foulks scoring), followed by conjunctival staining (NEI/Industry scale). [Lemp MA. Report of the National Eye Institute/Industry Workshop on Clinical Trials in Dry Eye. CLAO J. 1995;21:221-232.] [Foulks GN, Bron AJ. Meibomian Gland Dysfunction: A Clinical Scheme for Description, Diagnosis, Classification, and Grading. Ocul Surf. 2003;1(3):107-126.] If we accept as a given that at the time of a clinical visit each patient has a single severity of the disease, then we need to establish an objective method by which we define that severity, or truth. In lieu of a gold standard test, the next best thing is a composite severity scale that has a large number of tests in the index (to minimize the a priori bias for any one sign), as well as one that maintains equal correlation risk against the index for each sign so that you can objectively compare performance of the individual signs. In An objective approach to dry eye disease severity, we demonstrated that the average correlation coefficients for random data against the OS 3 severity index were: osmolarity (r 2 =0.10), TBUT (r 2 =0.15), Schirmers (r 2 =0.08), corneal staining (r 2 =0.09), conjunctival staining (r 2 =0.10), meibomian grading (r 2 =0.09), and OSDI (r 2 =0.24). Therefore, we know that the performance of signs is not due to inclusion in the composite, but actual relationship to overall disease severity. Section 1. Data Preparation In order to implement the composite, it is first necessary to transform the raw clinical data into a normalized basis on {0,1}. An expert panel of clinicians provided a modified version of the Dry Eye WorkShop (DEWS) severity scale as shown in Table 1 below, and either linear or exponential curves were created to fit the expert values, resulting in the readily invertible functions shown in Table 2. In the Excel file attached to this tutorial, raw clinical data is passed through the inverted equations to produce values ranging from 0 (representing the least evidence of disease) to 1 (representing the most evidence of dry eye). 920041 Rev B, TearLab Ocular Surface Severity Scale (OS3) 2010, TearLab Inc. - 1 -

Table 1. Quantified DEWS Severity Scale [No Authors Listed. 2007 Report of the International Dry Eye WorkShop (DEWS). Ocul Surf. 2007;5(2):65-204]. DED Severity Grade 0 1 2 3 4 Schirmer Test (mm) 35 7 5 2 0 TBUT (seconds) 45 7 5 3 0 Staining (NEI/Industry scale) 0 3 8 12 16 OSDI 0 15 30 45 100 Meibomian Grading Score 0 5 12 20 27 Osmolarity (mosms/l) 275 308 324 364 400 Table 2. Results of Continuous Mapping. To generate a severity value between {0,1}, clinical data is substituted into the inverted curves. For instance, a Schirmer value of 4 mm would be converted as 1.4063*ln((4+1)/35)/-5 = 0.55, which is equivalent to a value between the DEWS severity grades of 2 & 3. Similarly, a corneal staining value of 16 would be calculated as 16/16 = 1.00, representing the highest level of severity in that dimension. Note that to avoid an infinity at ln(0) for Schirmer tests, TBUT and OSDI, appropriate offsets were added to the argument of the inverted curves. Fitted Curve Inversion Schirmer Test (mm) 35e -5x 1.4063*ln((y+1)/35)/-5 TBUT (seconds) 45e -5x 1.3135*ln((y+1)/45)/-5 Staining (NEI/Industry scale) 16x y/16 OSDI 10e 2.38x -10 ln((y+10)/10)/2.38 Meibomian Grading Score 27x y/27 Osmolarity (mosms/l) 125x+275 (y-275)/125 920041 Rev B, TearLab Ocular Surface Severity Scale (OS3) 2010, TearLab Inc. - 2 -

Section 2. De Novo Independent Components Analysis Note: This section is only for people that want to develop their own composite index from signs other than those referenced above (e.g., if you want to incorporate other biomarkers, dynamic optical measurements, etc.). If you just want to use the index using the signs above, skip this section and go right to the Excel file. Novel input measurements also require that the data first be transformed onto {0,1}. Because several of the common signs for dry eye measure similar aspects of the disease process, (e.g. conjunctival and corneal staining), it is important to equalize the information content from each input variable before mixing them together into a composite, otherwise there is a potential for bias against the index. We implemented an independent components analysis to make sure the composite carried equal information from each part of the disease process. While beyond the scope of this document, there are many good tutorials on implementing ICA, for instance: http://www.cis.hut.fi/aapo/papers/ijcnn99_tutorialweb/ and http://www.nlpca.de/ica.html which contains a nice repository of code, including a link to EEGLAB. As we define the mean of the non-unique mixing matrix as our estimate of redundancy between the clinical measurements, the ICA is run multiple times to reach convergence. In this code it is only run twice to avoid long processing times. If compiled and run correctly, the output should look something like: 920041 Rev B, TearLab Ocular Surface Severity Scale (OS3) 2010, TearLab Inc. - 3 -

(Note: the Matlab code here makes use Jon Shlens infomax() and natgrad() function [http://www.snl.salk.edu/~shlens/], but we have also implemented it using runica() from the EEGLAB in case the Shlens code is unavailable). OS3 Ocular Surface Severity Scale 2010 Benjamin D. Sullivan, Ph.D. & TearLab Inc. Note data represents the most severe of a bilateral measurement data is an n x 7 matrix, with n = number of patients Each column in data represent a different clinical sign Ordered as: Osmolarity, TBUT, Schirmers, Cornea, Conjunctiva, Meibomian, OSDI clear all data=[303 9.7 18 0 0 0 20.8 321 3 0 11 8 4 33.3 309 3.3 8 2 2 4 22.9 323 1.7 5 1 2 2 31.3 292 3 9 5 12 2 41.7 318 2.7 14 8 6 0 70.5... 317 1 20 2 5 0 4.2 332 2 15 0 4 0 10.4 317 2 2 2 12 9 43.2]; datalength=size(data,1); Normalize data by DEWS severity scale datas(:,1)=(data(:,1)-275)/125; datas(:,2)=1.3135*log((data(:,2)+1)/45)/-5; datas(:,3)=1.4063*log((data(:,3)+1)/35)/-5; datas(:,4)=data(:,4)/16; datas(:,5)=data(:,5)/12; datas(:,6)=data(:,6)/27; datas(:,7)=log((data(:,7)+10)/10)/2.38; nn=7; d2=datas(:,1:nn); d5=d2-repmat(mean(d2),datalength,1); mean subtracted data [U,S,V]=svd(d5'); subplot(2,1,1) plot(1*(abs(u(:,1)/sum(u(:,1))))) set(gca,'ylim',[0 15]) title('principal Components Analysis, via SVD') set(gca,'xticklabel',{'osmolarity','tbut','schirmers','cornea','conjunctiva','meibomian', 'OSDI'}) Aa=zeros(nn,nn); mm=2; for i=1:mm [signals, A, W] = infomax(d5'); Aa=A+Aa; end A=Aa/mm; subplot(2,1,2) plot(1*(abs(mean(a'))/sum(abs(mean(a'))))) title('average Independent Components') set(gca,'xticklabel',{'osmolarity','tbut','schirmers','cornea','conjunctiva','meibomian', 'OSDI'}) redundancy=1*(abs(mean(a'))/sum(abs(mean(a')))) 920041 Rev B, TearLab Ocular Surface Severity Scale (OS3) 2010, TearLab Inc. - 4 -

Section 3. Severity calculation Open TearLabOS3.xls a Microsoft Excel 2004 document. Input values manually, or use the Paste Special : Values command to enter data into the OD and OS columns of the respective objective clinical tests. The severity result will be displayed in the far right Column. Note that if a value is missing, the formula will return a blank result. Redundancy (from ICA) Osm TBUT Sch Cor Conj Meib OSDI 0.09 0.13 0.16 0.13 0.14 0.14 0.21 OD OS Subject Osm TBUT Sch Cor Conj Meib Osm TBUT Sch Cor Conj Meib OSDI Severity 1 286 10 18 0 0 0 303 9.7 28 0 0 0 20.8 0.23 2 298 3 0 11 7 4 321 5.7 0 11 8 4 33.3 0.59 3 309 3.3 8 1 2 4 307 4.3 8 2 1 4 22.9 0.34 4 323 2.7 5 0 2 2 322 1.7 8 1 2 2 31.3 0.41 5 303 2.7 14 8 6 0 318 3 17 8 4 0 70.5 0.46 The severity formula in Excel, for the first subject with blank checking: =IF(OR(ISBLANK(B10),ISBLANK(C10),ISBLANK(D10),ISBLANK(E10),ISBLANK(F10),ISBLANK(G10),ISBLANK(H10),ISBLANK(I10),ISBLANK(J10),ISBLANK(K10),ISBLA NK(L10),ISBLANK(M10),ISBLANK(N10)),"",SQRT(SUM((((LN((N10+10)/10)/2.38)/$H$6)^2)+(((1.3135*LN((MIN(C10,I10)+1)/45)/(- 5))/$C$6)^2)+(((1.4063*LN((MIN(D10,J10)+1)/35)/(-5))/$D$6)^2)+(((MAX(E10,K10)/16)/$E$6)^2)+(((MAX(F10,L10)/12)/$F$6)^2)+((((MAX(B10,H10)- 275)/125)/$B$6)^2)+(((MAX(G10,M10)/27)/$G$6)^2)))/SQRT(SUM((1/$C$6^2)+(1/$D$6^2)+(1/$E$6^2)+(1/$F$6^2) +(1/$G$6^2)+(1/$H$6^2)+(1/$B$6^2)))) 920041 Rev B, TearLab Ocular Surface Severity Scale (OS3) 2010, TearLab Inc. - 5 -